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Abstract
The human gastrointestinal tract harbors a complex and abundant microbial community reaching
as high as 1013–1014 microorganisms in the colon. This endogenous microbiota forms a symbiotic
relationship with their eukaryotic host and this close partnership helps maintain homeostasis by
performing essential and non-redundant tasks (e.g. nutrition/energy and, immune system balance,
pathogen exclusion). Although this relationship is essential and beneficial to the host, various
events (e.g. infection, diet, stress, inflammation) may impact microbial composition, leading to the
formation of a dysbiotic microbiota, further impacting on health and disease states. For example,
Crohn’s disease and ulcerative colitis, collectively termed inflammatory bowel diseases (IBD),
have been associated with the establishment of a dysbiotic microbiota. In addition, extra-intestinal
disorders such as obesity and metabolic syndrome are also associated with the development of a
dysbiotic microbiota. Consequently, there is an increasing interest in harnessing the power of the
microbiome and modulating its composition as a means to alleviate intestinal pathologies/
disorders and maintain health status. In this review we will discuss the emerging relationship
between the microbiota and development of colorectal cancer as well as present evidence that
microbial manipulation (probiotic, prebiotic) impacts disease development.
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1. Introduction
Higher vertebrates have intimately co-existed with a myriad of microorganisms throughout
evolution and this relationship has proven mutually beneficial for both entities. Although
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numerous external and internal surfaces are colonized by microorganisms, the human
gastrointestinal (GI) tract represents the most abundant reservoir of microbes. It is estimated
that the intestinal tract harbors over 100 trillion bacteria regrouped in about 1000 species.
The collective prokaryote community outnumbers eukaryote cells in the human body by a
factor of 10 and their collective genome is 100 times more abundant than the host genome
[1]. We are now just beginning to understand the genomic composition and contribution of
the microbiota to intestinal homeostasis. This vast microbial community is rapidly acquired
through close contact with the mother microbiota including passage through the birth canal,
breast feeding and skin contact [2]. These various modes of microbial exposures clearly
impact on the intestinal microbiota composition since naturally delivered infants have a
larger number of bifidobacteria species than did babies delivered by caesarean section [3].
In addition, Bifidobacterium are the prevalent genus in breast-fed infants whereas
Enterococci prevail in formula-fed infants [4]. The functional implication of early
differential colonization is unclear but tantalizing observations suggest a relationship with
disease susceptibility [5–7]. For example, the intestinal microbiota in children from Europe
and rural Africa who are exposed to a modern western diet and a rural diet respectively,
have significant differences in microbial composition. The major difference was that rural
Africa children showed a significant enrichment in Bacteroidetes and depletion in
Firmicutes when compared to European children [7]. These differences may well explain the
higher incidence of IBD in Europe than Africa [8]. In addition, microbial composition is
modulated by numerous extrinsic factors such as diet, age, medication (antibiotics,
NSAIDs), treatment (radiation, surgery), stress and disease [9]. However, our current lack of
knowledge about microbiome core (microbial community) plasticity prevents the
establishment of a health/disease microbial threshold. Nevertheless, it is clear that various
biological and physical situations impact microbial composition, with some of these changes
linked to disease development. It is not surprising that diseases of GI origin such as IBD and
colorectal cancer have been subjected to increasingly intense investigation of the microbiota.
2. Endogenous microbiota, risk factors and development of colorectal
cancer
Colorectal cancer (CRC) is among the most common worldwide cancers, accounting for
over 1 million cases and about half a million deaths annually [10]. The incidence rates of
CRC are higher in the Western world but are rapidly increasing in developing countries. The
main two contributing factors to the occurrence of CRC are genetic (15%) and
environmental factors [11]. In addition, inflammatory conditions have been shown to favor
the development of CRC as patients with IBD have an annual risk increase of 1%/year (10
years post-diagnosis) [12]. Another emerging factor involved in CRC susceptibility is the
intestinal microbial composition. Since the microbiota impacts numerous physiological
functions related to cancer risk including control of epithelial cell proliferation/
differentiation, production of essential nutrients and/or bioactive food components,
prevention of overgrowth of pathogenic organisms and stimulation of intestinal immunity,
recent efforts have been directed at defining the microbiota of CRC. Although few studies
have tackled microbial composition in human CRC, recent reports have indicated
differences between the microbiome of patients and healthy subjects. For example, the stool
of CRC patients harbored increased Bacteroides-Prevotella populations compared to normal
controls [13]. Another study investigated bacterial communities present at the intestinal
mucosal surface of patients with adenoma. Interestingly, at the genus level, patients with
adenomas showed increased abundance of Dorea spp., Faecalibacterium spp. and lower
proportions of Bacteroides spp. and Coprococcus spp. than non-adenoma subjects [14]. This
finding revealed that alterations in bacterial community composition is associated with
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CRC; although at this point, it is unclear whether these changes preceded disease onset or
simply reflect a consequence of the disease.
Interestingly, factors influencing CRC development (age, NSAID, diet) were also
demonstrated to impact on microbial composition. For example, Mäkivuokko et al. [15]
reported that there was a significant reduction in overall numbers of microbes in elderly
subjects compared with young adults. Moreover, lower numbers of Firmicutes and an
increased proportion of Bacteroidetes in the elderly were observed in this study.
Furthermore, the total number of microbes was higher and lower numbers of Collinsella spp.
were evident in the elderly subjects who take NSAID compared both with young adults and
the elderly who do not take NSAID on a regular basis. Enck et al. [16] reported that
individual bacterial species consistently and significantly increased with age (E. coli,
Enterococci spp.), decreased at an older age (Bacteroides spp.), or were stable throughout
the life span (Lactobacilli, Bifidobacteria). These results suggest that the use of NSAIDs,
combined with age, may influence the process of tumorigenesis by changing the
composition of the intestinal microbiota.
High animal protein intake and a high fat diet are additional risk factors associated with
colon cancer. Americans who have a high colon cancer risk typically consume a high-animal
protein and fat diet, whereas Africans, who have the lowest colon cancer risk, consume a
staple diet of maize meal, rich in resistant starch. O’Keefe et al. [17] analyzed the contents
of colon in native Africans and African Americans and Caucasian Americans. Butyrate is
produced by specific colonic bacteria, predominantly Clostridia clusters XIVa and IV of
Firmicutes, from food residues such as dietary fiber or resistant starch. Their results
demonstrated that the colonic content of butyrate, and all of the chief short chain fat acids
(SCFA) produced by bacterial fermentation of undigested carbohydrates, were significantly
higher in native Africans compared with African Americans and Caucasian Americans. In
another study [18], fecal colony counts of 7-adehydroxylating bacteria were higher and
Lactobacilli were lower in African Americans compared to Caucasians and colonic crypt
cell proliferation rates were also higher in African Americans. These studies provide
evidence that higher dietary intakes of animal products may alter the gut microbiota and
therefore play a key role in carcinogenesis.
Obesity is a closely related risk factor of human CRC. Numerous studies [19–23] have
verified the association between an alteration of the dominant phyla of bacteria in the gut
and body weight, both in humans and animal models. The gut microbes have been shown to
impact insulin resistance, inflammation, and adiposity via interactions with epithelial and
endocrine cells. The intestinal epithelia cells (IECs) have a complex and mutually beneficial
relationship with the gut flora. The bacteria metabolize some nutrition components in the
gut, e.g. carbohydrates; in turn, the IECs metabolize the short-chain fatty acids and use them
as a source of energy. In fact, the gut microbial community is essential for processing
dietary polysaccharides. Bäckhed et al. [24] found that adult germ-free (GF) C57BL/6 mice
given a normal microbiota harvested from the cecum of conventionally raised animals
results in a 60% increase in body fat content and insulin resistance within 14 days, despite
reduced food intake. Furthermore, colonization of GF mice with an “obese microbiota”
results in a significantly greater increase in total body fat than colonization with a “lean
microbiota”. These results identify the gut microbiota as an additional contributing factor to
the pathophysiology of obesity.
The increasing understanding of GI barriers, and the adjacent GI microbiota provide
evidence that these two functional entities are key to achieving and maintaining gut health
[25,26]. Gut microbiota contribute to the maintenance of an intact GI barrier and disruption
of this barrier can impact inflammatory and allergic diseases. The GI barrier refers to a
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functional entity consisting of epithelial defense and metabolic functions, the mucosal
immune system and the enteric nervous system (ENS) [25]. The formation of an intestinal
mucus layer is an important physical barrier protecting the intestinal epithelium against
invasive micro-organisms. The mucus layer is formed by various mucin proteins which are a
family of heavily glycosylated proteins including mucin1, mucin 2, mucin 3a and others.
Mucins are produced mostly by Goblet cells. Mucin 2 (MUC2), the principal component of
intestinal mucus, along with small amounts of related-mucin proteins, polymerizes into a gel
that provides an insoluble mucous barrier that serves to protect the intestinal epithelium,
Another important epithelial cell involved in bacteria-host interactions are the Paneth cells,
which are critical for the maintenance of the intestinal barrier by producing zinc and
antimicrobial peptides. The combined action of Goblet and Paneth cells has a significant
impact on microbial composition and GI barrier function [27, 28]. Altered MUC2
expression and/or glycosylation leads to accompanying intestinal pathologies, including IBD
and colon cancer [29]. The generation of a MUC2 mutant mouse model, alone or in
combination with an Apc mutation, had unique pathophysiologic features useful for
dissecting complex relationships between tumor development and chronic inflammation
[30]. Paneth cells directly sense enteric bacteria through cell-autonomous MyD88-dependent
toll-like receptor (TLR) activation, triggering expression of multiple antimicrobial factors
[31]. E-cadherin is a major component of adherens junctions, which play a key role in
intestinal homeostasis and barrier function. Impaired expression of E-cadherin was linked to
maturation and positioning of Goblet cells and Paneth cells in the murine small intestine and
colon [32].
Cheese whey protein is rich in the amino acids of threonine and cysteine and promotes
synthesis of mucin. In the model of dextran sulfate sodium (DSS), which is an irritant that
causes colonic inflammation (colitis) by eroding the mucosal barrier, feeding rats with a diet
containing cheese whey protein reduced gene expression of inflammation markers and
increased fecal mucin secretion and fecal lactobacilli and bifidobacteria counts [33].
Furthermore, the number of Goblet cells in the small intestine increased by the simultaneous
incubation of Bifidobacterium bifidum IATA-ES2 with wheat gluten proteins, IFN-γ and
enterobacteria using the rat intestinal loop model [34]. Thus, dysbiosis could be involved in
the damage of the GI barrier and it is clear that further research is needed to fully elucidate
the complex interactions between the microbiota and the GI barrier.
3. Gut microbiota, innate signaling, inflammation and colon carcinogenesis
The inter-relation between bacteria and inflammation is complex as bacteria and
inflammation could mutually impact upon each other. This interaction can, in turn, modulate
development of CRC (see Fig. 1). As diagrammed in the figure, the types and level of
activation of the various innate sensors can influence the gene expression pathways, level of
inflammation and the consequences of these changes on DNA damage and chromatin
alterations, which when combined with host genetic factors can lead to tumorigenesis.
However, tumorigenesis is complicated and a linear association between dysbiosis-
inflammation-tumorigenesis is not fully supported by other studies. Swidsinski et al [35]
showed that adherent/invasive E. coli strains are found in high abundance on the colonic
mucosa of patients with colorectal carcinoma and adenoma but not normal colonic mucosa,
leading to hypothesis that E. coli colonization in the colon may indicate a specific
microorganism can be responsible for malignant pathology. In contrast, Burn et al. [36]
reported that the use of aspirin and/or resistant starch had no effect in hereditary
nonpolyposis colon cancer. Moreover, while microsatellite instability (MSI) have been
documented in dysplasia and development of CRC, Goel et al. [37] reported that treating
ulcerative colitis patients with mesalazine or Escherichia coli Nissle for a year did not show
improvement in the prevalence of MSI in the distal colon. Likewise, as suggested by other
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studies [13, 14], additional regulatory pathways exist between dysbiosis and tumorigenesis,
other than inflammation.
Experimental models have addressed the individual and collective role of microorganisms in
the development of inflammation and CRC. For example, Enterotoxigenic Bacteroides
fragilis (ETBF) secretes B. fragilis toxin (BFT) and causes human inflammatory diarrhea
but also asymptomatically colonizes a proportion of the human population. In another
animal study [38], GF IL-10−/− or WT mice were monoassociated with Bifidobacterium
animalis subsp. The bacteria caused mild colitis in monoassociated IL-10−/− mice, whereas
the intestinal tracts of WT animals remained free of inflammation. The result suggested a
potential pathogenic role for this commensal bacterial species in a susceptible host. Wu et al.
[39] indicated that mice chronically colonized with ETBF developed colitis and induced
colonic tumors in multiple intestinal neoplasia (MIN) mice. Uronis et al. [40], showed that
conventionalized IL10−/− mice exposed to the procarcinogenic compound azoxymethane
(AOM) developed spontaneous colitis and colorectal carcinomas while AOM-WT mice
were colitis-free and mostly developed low grade dysplasia. Interestingly, the bacterium
Bacteroides vulgatus caused low level inflammation in IL10−/− mice, resulting in reduced
colorectal tumors as compared to conventionalized IL10−/− mice. Moreover, GF AOM-
treated IL10−/− mice showed no intestinal inflammation or CRC. The results support the
concept that specific microbial entities differently impact on the development of intestinal
inflammation and CRC. The molecular mechanism by which bacteria affect the
development of intestinal inflammation and cancer is unclear but may be related to the
triggering of a series of innate sensors responsible for microbial detection.
A number of studies have addressed the role of the host innate immune system in regulating
carcinogenesis. The most studied innate sensors relating to colitis and CRC are the Nod-like
receptors (NLR) and the Toll-like receptors (TLR). The interaction of gut microbiota and
epithelial cells is an active process, in which NLRs and TLRs are likely directly involved.
Colitis-associated cancer (CAC) is a colorectal disease where cancer arises in patients
suffering from long bouts of chronic intestinal inflammation. CAC can be modeled in mice
by injection of the AOM and by repeated exposure to DSS. Using a mouse model system of
CAC (AOM-DSS), Chen et al. [41] demonstrated that tumors increased in Nod1-deficient
mice compared to wild type mice. In addition, ApcMIN/+Nod1−/− mice, which harbor a
mutation in Apc and are also deficient in Nod1, developed more tumors. This result suggests
that Nod1 pathway could enhance the tumor-promoting effect of attenuated Wnt signaling.
Additionally, depletion of the gut microbiota using antibiotic treatment suppressed tumor
development in Nod1-deficient mice. Furthermore, NLRP3-signaling from immune cells
was recently shown to play a protective role against colitis and CAC [42]. Additionally,
NLRP6 has recently been shown to prevent development of CAC [43]. All together, these
data support a role of the host innate immune signaling pathways in the regulation of
inflammation-mediated colon cancer development.
Toll-like receptors (TLRs) belong to the Toll-like receptor/interleukin-1 receptor (TLR/
IL-1R) superfamily which is defined by a common cytoplasmic Toll/interleukin-1 receptor
(TIR) domain. The single immunoglobulin IL-1 receptor-related molecule (SIGIRR), a
negative regulator for Toll-IL-1R signaling, plays a critical role in gut homeostasis,
intestinal inflammation, and colitis-associated tumorigenesis by maintaining the microbial
tolerance of the colonic epithelium [44–47]. Cells from SIGIRR-deficient mice showed
enhanced activation in response to either IL-1 or certain Toll ligands [44]. In human colonic
samples, SIGIRR was expressed mainly in IECs at levels significantly higher in inactive
compared to active mucosa. In mice, colonic SIGIRR expression decreased rapidly after
colitis development and returned gradually to basal levels [46]. SIGIRR may exert its
inhibitory effect through blocking the molecular interface of TLR4, TLR7 and the MyD88
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adaptor mainly via its BB-loop region [47]. Moreover, the innate adapter protein MyD88
prevents the development of CAC by transmitting IL-18 receptor signaling [48]. In contrast,
TLR4 promotes the development of CRC in the AOM/DSS model [49]. TLR4 is expressed
on CD4+ T cells and TLR4 triggering in CD4+ T cells affects their phenotype and their
ability to provoke intestinal inflammation. In a model of spontaneous colitis [50],
IL10−/−TLR4−/− mice displayed accelerated development of disease, with signs of overt
colitis as early as 8 week of age, when compared with IL10−/− and IL10−/−TLR9−/− mice
which did not develop colitis by 8 months. Mechanistically, Lipopolysaccharide (LPS)
stimulation of TLR4-bearing CD4+ T cells inhibited ERK1/2 activation upon subsequent
cell stimulation. These data highlighted the complex relationship between the microbiota
and the status of inflammation and CRC in the host and supported the model where
susceptibility to develop CRC is modulated by the microbiota and by the repertoire of host
innate sensors. Consequently, modulation of the intestinal microbiota using probiotics or
prebiotics could influence the development of tumors.
4. Probiotics and colon cancer
The term “probiotics” has been in use for several decades and the Food and Agriculture
Organization of the United Nations and World Health Organization Expert Consultation
defined the term in 2001 as “live micro-organisms which confer a health benefit on the host
when administered in adequate amounts”[51]. Lactic acid bacteria and Bifidobacteria are
the most common types of microbes used as probiotics, while certain yeasts and bacilli may
also be beneficial to the host. The immunomodulatory effect of probiotic bacteria has been
postulated by Metchnikoff over 100 years ago [52]. There has been an increased interest in
the scientific community on the protective roles of probiotics on intestinal diseases,
especially IBD and colon carcinogenesis. A meta study [53] in 2006 showed that most of the
studies (epidemiological and interventional) evaluating the effect of probiotics
administration on the incidence of CRC and/or of precursor lesions had positive results
although the authors of this publication argue that “There are no positive data from
interventional studies so far.”
4.1. In vitro studies
The precise mechanisms by which probiotics inhibit colon cancer may involve multiple
pathways, including cell cycle, reactive oxygen species (ROS), apoptosis, production of
specific bacterial enzymes and effects on the host metabolome. Polyamine synthesis is an
early event during the G1 phase of the cell cycle and is necessary for cells to initiate their
proliferative processes. Orlando et al. [54] found that Lactobacillus GG administration
induced a significant reduction in polyamine biosynthesis in both the HGC-27 and DLD-1
cancer cell lines. The antiproliferative effect of the probiotic microorganisms was observed
after 24 hours of the treatment. The anti-proliferative capabilities of probiotics may also
relate to their ability to adhere to cells. Lee et al. [55] found that Bacillus polyfermenticus
SCD was strongly adherent to Caco-2 cells and inhibited the growth of colon cancer cells in
a dose dependent manner. Kim et al. [56] assessed the anticancer activity and bacterial
enzyme inhibition of Bifidobacterium adolescentis SPM0212. The strain inhibited the
proliferation of three human colon cancer cell lines: HT-29, SW 480, and Caco-2 and also
dose-dependently inhibited TNF-α production and changes in cellular morphology. This
specific bacterial strain could inhibit harmful fecal enzymes, including β-glucuronidase, β-
glucosidase, tryptophanase, and urease.
The interaction of gut microbiota and epithelial cells is an active process, in which some
proinflammatory cytokines are induced by probiotics from epithelial cells. TLRs are likely
directly involved in this process. Paolillo et al. [57] reported Caco-2 cells exposed to L.
plantarum bacteria significantly induced human beta-defensin 2 (HBD-2) mRNA expression
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and HBD-2 secretion in a time dependent manner compared to controls. The L. plantarum-
induced increase in HBD-2 expression was inhibited by anti-TLR-2 neutralizing antibodies.
Some strains of Lactobacilli can stimulate macrophages and dendritic cells to secrete IL-12,
a cytokine that plays a key role in activating innate immunity. Shida et al [58] examined the
IL-12-inducing ability in mouse peritoneal macrophages of 47 Lactobacillus strains
belonging to 10 species. Almost all strains belonging to the Lactobacillus casei group or to
Lactobacillus fermentum induced high levels of IL-12 and phagocytosis of the Lactobacilli
was necessary for the IL-12 induction. Their results also demonstrated that Lactobacillus
strains having a rigid cell wall resistant to intracellular digestion effectively stimulate
macrophages to induce IL-12.
4.2. In vivo experiments
Probiotics contribute to the development of the mucosal immune system by influencing the
innate inflammatory response and reducing mucosal inflammation. Probiotics also act
through effects on dendritic, epithelial cells, native T cells in the lamina propria of the gut
and can thus influence adaptive immunity. Previous studies have demonstrated the anti-
inflammatory effect of probiotics on intestinal inflammation. Lactic acid bacteria are present
in many foods, such as yogurt, and are frequently used as probiotics to improve some
biological functions of the host. Perdigon et al. [59] found that yogurt induced a great
reduction in the inflammatory immune response and inhibited tumor growth in 1,2-
dimethylhydrazine(DMH) treated BALB/c mice. In addition, they observed an increase in
the IgA-secreting cells and in CD4+ T lymphocytes. A yogurt based formulation containing
microencapsulated live probiotic bacterial cells has been used in colon cancer prevention
and therapy studies. Urbanska et al. [60] studied the properties of microencapsulated
probiotic bacterial cells in a yogurt formulation in MIN mice carrying a germline APC
mutation. Daily oral administration of the microencapsulated Lactobacillus acidophilus
resulted in significant suppression of colon tumor incidence, tumor multiplicity, and reduced
tumor size. Furthermore, treated animals exhibited fewer GI intra-epithelial neoplasia with a
lower grade of dysplasia in tumors. The immunomodulating and immunostimulating
properties of yogurt and fermented milks have also been well documented. Yogurt feeding
itself was correlated with increased or decreased levels of some cytokines, such as TNFα,
IFN-γ and interleukins [59–60]. Interestingly, Pagnini et al. [61] reported that probiotics
may promote gut health through stimulation, rather than suppression, of the innate immune
system. They reported that the multiple probiotic formulation VSL#3 (Streptococcus
thermophilus, Bifidobacterium infantis, and Lactobacillus acidophilus) could prevent the
onset of ileitis in the SAMP1/YitFc murine model by local stimulation of epithelial innate
immune responses, i.e. increased production of epithelial-derived TNF-α and restoration of
the epithelial barrier function in vivo. Leblanc et al. [62] reported that a yogurt diet given to
BALB/c mice before and after the carcinogen 1, 2-dimethylhydrazine (DMH) treatment,
inhibited tumor formation. In the DMH-yogurt group, cellular apoptosis increased during the
treatment. Yogurt feeding induced TNF-α and IFN-γ expression in cells isolated from large
intestine nodules and the expression of these cytokines also increased in cells obtained from
Peyer’s Patches of the yogurt control group.
Another key player in colon inflammation is the presence of reactive oxygen species (ROS)
and the antioxidant properties of probiotics may contribute to their broad effects [63].
Likewise, polyphenols from tea and other beverages such as red wine can play a role as
possible chemopreventive agents by reducing oxidative damage, and result in an increase in
gut colonization by some probiotics strains [64]. Park et al. [65] assessed the effects of
Bacillus polyfermenticus on the antioxidant system and the process of colon carcinogenesis
in male F344 rats. The rats fed with Bacillus polyfermenticus exhibited significantly lower
numbers of aberrant crypt foci than were observed in the DMH treated group. Leukocytic
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DNA damage and plasma lipid peroxidation levels, as well as a lower plasma total
antioxidant potential, recovered in response to supplementation with Bacillus
polyfermenticus. These results indicated that Bacillus polyfermenticus could exert a
protective effect on the antioxidant system and the process of colon carcinogenesis.
An underlying mechanism that might be involved in the activity of probiotics may be the
induction of apoptosis. Apoptosis induction by commensal bacteria could possibly represent
a physiologic “oncologic surveillance” mechanism for colonic proliferative disease
prevention [66], but this hypothesis awaits further testing for confirmation.
5. Prebiotic and synbiotics
Prebiotics are non-digestible food ingredients that stimulate the growth and/or activity of
bacteria in the digestive system in ways claimed to be beneficial to health. Synbiotics refer
to nutritional supplements combining probiotics and prebiotics that are thought to act
together; i.e. synergism. It has been suggested that a combination of a probiotic and a
prebiotic, i.e. synbiotics, might be more active than either a probiotic or prebiotic alone in
preventing CRC. A high olive oil-containing diet supplemented with a freeze-dried fruit and
vegetable extract (OFV), increased the family Lachnospiraceae in Apc (MIN) mice and
reduced the development of intestinal adenomas in this model [67]. As another example, Le
Leu et al. [68] evaluated the effect of bacteria Bifidobacterium lactis and “resistant starch”
(RS) and their combination (synbiotic) on their ability to protect against CRC.
Bifidobacterium lactis utilizes the carbohydrate “resistant starch” (RS) as a substrate and up-
regulates the acute apoptotic response to a carcinogen in the colon. Rats fed RS in
combination with Bifidobacterium lactis showed a significantly lowered incidence and
multiplicity of colonic neoplasms compared with the control group. No protection against
cancer was seen in the group supplemented with only Bifidobacterium lactis. Interestingly, a
fermented milk product containing Bifidobacterium animalis subsp. lactis DN-173 010
strain protects against development of colitis in the T-bet−/−; Rag2−/− mice through
reduction of colitogenic microorganisms, microorganisms that favorthe development of
colitis [69]. In addition, mice exposed to sialyl (alpha2,3) lactose-deficient milk were more
resistant to DSS-induced colitis, which again is associated with the reduction of potentially
colitogenic microorganisms[70]. In another diet based study, Lara-Villoslada et al. [71]
reported short-chain fructooligosaccharides(SC-FOS) increased cecal Lactobacilli and
Bifidobacteria counts as well as short-chain fatty acid (SCFA) production in healthy rats. In
colitic rats, SC-FOS feeding caused a decrease of MPO activity, leukotriene B4 (LTB4)
production and iNOS expression. This anti-inflammatory effect was evidenced by a
significant reduction in the extent of colonic damage. Thus there is a growing body of data
indicating that specific bacterial species, in combination with dietary changes/additions, can
modulate overall gut inflammation. Long term studies are now needed to assess the impact
of these mechanisms of reducing gut inflammation on CRC.
6. Clinical trials
Despite the experimental evidence in rodent models showing a beneficial effect of probiotics
that inhibits the development of CRC, a systemic approach for the evaluation of probiotics
leading to the substantiation of health claims in humans is very limited. A FAO/WHO
Working Group has generated guidelines for the criteria and methodology for evaluation of
probiotics in clinical trials [72]. Since then, several studies have been reported, generally in
the form of randomized, double- blinded, measurement of efficacy and side effect compared
with placebo. In one study the administration of Lactobacillus casei was tested as a method
to prevent the occurrence of colorectal tumors [73]; the occurrence of tumors with a grade of
moderate atypia or higher was significantly lower in the patient group after 2–4 years treated
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with Lactobacillus casei as compared to the control group. In a 12-week clinical trial [74]
completed in 2007, polypectomized patients were treated with Lactobacillus rhamnosus GG
(LGG) and Bifidobacterium lactis Bb12 (BB12) and oligofructose-enriched inulin. The
treatment resulted significant changes in fecal flora of the patients as Bifidobacterium and
Lactobacillus increased and Clostridium perfringens decreased. The intervention also
significantly reduced colorectal proliferation in the patients. A two-period crossover study
on 38 healthy men was reported with treatment periods of 4 weeks of Lactobacillus
rhamnosus LC705 (LC705) together with Propionibacterium freudenreichii ssp shermanii
JS (PJS) [75]. The administration of LC705 and PJS was followed by an increase in the
fecal counts of Lactobacilli and Propionibacteria and a decrease in the activity of β-
glucosidase with increasing counts of Propionibacteria. Recently, Gianotti et., al [76],
reported in a prospective trial that in 31 CRC patients, Lactobacilli johnsonii (La1), but not
Bifidobacterium longum (BB536), affects intestinal microbiota by reducing the
concentration of pathogen and modulating the intestinal immune response. Thus, in clinical
trials, probiotics are suggested to play a protection role in the initial process of
carcinogenesis. However, it remains to be determined if long term administration of
probiotics can result in significant changes in the incidence of CRC in humans. Recently, a
cohot study with 12 years of follow-up on 45,241 volunteers determined that high yogurt
intake was significantly associated with decreased CRC. risk, suggesting the long term
administration of probiotics or probiotics formulations can reduce the incidence of CRC
[77]. Some of the challenges faced in these studies will be the selection and standardization
of the appropriate microorganisms, control for dietary intake, time and frequency of
microorganism dosing and development of biomarkers that can be followed over the long
term course of any such clinical trials.
7. Conclusions
There is a growing body of evidence that the gut microbiota contributes to colon
tumorigenesis. Animal experiments have revealed that microorganisms can directly impact
gut immunity and inflammation but statistically and biologically significant evidence of
such effects is still needed in human trials. Probiotics can inhibit the inflammatory process
by enhancing host immune responses, altering the bacterial phylotypes in the colon and
impacting the gut metabolome. They may also have anti-tumor properties through direct
anti-proliferative activity on tumor cells. However, further experimental models are needed
to better understand the exact mechanisms involved in the effects of probiotics on the host.
The results of these studies will hopefully lead to more rational and standardized approaches
for the use of probiotics in the prevention and treatment of human colorectal cancer.
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The evolving relationship between colon dysbiosis, inflammation and tumorigenesis.
Experimental models have addressed the individual and collective role of microorganisms in
the development of inflammation and CRC. Dysbiosis-inflammation-tumorigenesis provides
an important model of carcinogenesis in the human colon. Please refer to the text for a more
detailed discussion.
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